Shanghai Chest Hospital
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1957-01-01
- Employees
- -
- Market Cap
- -
Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC
Phase 1
Not yet recruiting
- Conditions
- Advanced Lung CancerRefractory TumorKRAS Mutation-Related Tumors
- Interventions
- First Posted Date
- 2024-06-13
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT06456138
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, China
Efficacy and Safety of Multimode Thermal Therapy in the Treatment of Early Peripheral Lung Cancer
Not Applicable
Not yet recruiting
- Conditions
- Lung Cancer
- Interventions
- Device: Multimode thermal therapy
- First Posted Date
- 2024-06-12
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT06453889
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
A Study of Molecular Residual, Dynamic Monitoring and Recurrence of Stage III Driver Mutated NSCLC
Recruiting
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Diagnostic Test: MRD
- First Posted Date
- 2024-06-05
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 305
- Registration Number
- NCT06443684
- Locations
- 🇨🇳
Affiliated Cancer Hospital of Harbin Medical University, Harbin, Heilongjiang, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳Shandong Provincial Hospital, Jinan, Shandong, China
Neoadjuvant Therapy of SBRT Sequencial with Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH)
Phase 3
Recruiting
- Conditions
- Stage II-III Non-small Cell Lung Cancer
- Interventions
- Radiation: SBRT
- First Posted Date
- 2024-05-31
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 478
- Registration Number
- NCT06437977
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, China
Neoadjuvant PD-1 Blockade for Elderly Esophageal Squamous Cell Carcinoma (BLESS)
Phase 2
Recruiting
- Conditions
- Esophageal Cancer
- Interventions
- Drug: neoadjuvant anti-PD-1Drug: neoadjuvant anti-PD-1 with LDRT
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT06385730
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
Predicting Non-small Cell Lung Cancer (NSCLC) Lymph Node Metastasis: Integrating Circulating Tumor DNA (ctDNA) Mutation/ Methylation Profiling With Positron Emission Tomography-computed Tomography (PET-CT) Scan
Recruiting
- Conditions
- Non-small Cell Lung CancerCarcinoma
- Interventions
- Procedure: MRD+ methylation (or combined with PET-CT) and Invasive mediastinoscopy /EBUS-TBNAProcedure: Intraoperative lymph node dissectionProcedure: Blood ctDNA + methylation + PET-CT and Postoperative pathology
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT06358222
- Locations
- 🇨🇳
Shanghai Chest Hospital, ShangHai, China
Prediction of Anastomotic Complications and Recurrent Laryngeal Nerve Injury Based on Postoperative Early Endoscopic Evaluation
Recruiting
- Conditions
- Esophageal NeoplasmAnastomotic StenosisAnastomotic LeakRecurrent Laryngeal Nerve InjuriesEndoscopic Evaluation
- First Posted Date
- 2024-04-04
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 250
- Registration Number
- NCT06348381
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China
Association of Psychological Distress in Patients With Lung Cancer
Recruiting
- Conditions
- Lung NeoplasmsIMMUNOTHERAPYTargeted Molecular TherapyPsychological DistressPrognosis FactorsLifestyle, Healthy
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 500
- Registration Number
- NCT06218901
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
Blinded Randomized Controlled Trial of Artificial Intelligence Guided Detection of Intracardiac Thrombus
Not Applicable
Not yet recruiting
- Conditions
- Atrial Fibrillation
- Interventions
- Other: Electrophysiologist judgment of the intracardiac thrombusOther: Automated detection of the intracardiac thrombus through deep learning
- First Posted Date
- 2024-01-16
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 1500
- Registration Number
- NCT06206187
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, 上海市, China
Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical Trial
Phase 2
Not yet recruiting
- Conditions
- Esophageal Squamous Cell Carcinoma
- First Posted Date
- 2023-12-20
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT06178211
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath